ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ORGO Organogenesis Holdings Inc

2.78
0.00 (0.00%)
Pre Market
Last Updated: 09:00:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Organogenesis Holdings Inc NASDAQ:ORGO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.78 2.45 3.96 0 09:00:01

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

10/07/2023 12:30pm

GlobeNewswire Inc.


Organogenesis (NASDAQ:ORGO)
Historical Stock Chart


From Nov 2022 to Nov 2024

Click Here for more Organogenesis Charts.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, August 9th.

Management will host a conference call at 5:00 p.m. Eastern Time on August 9th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com

Press and Media Inquiries:
Organogenesis
Ron O’Brien
communications@organo.com

1 Year Organogenesis Chart

1 Year Organogenesis Chart

1 Month Organogenesis Chart

1 Month Organogenesis Chart

Your Recent History

Delayed Upgrade Clock